Home / Market News / $LFCR

$LFCR news and market catalysts

The 7 most recent market catalysts affecting $LFCR, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

7 catalysts 2 high impact 1 bullish 3 bearish Biotechnology
Nov 4, 2026 Corporate Catalyst Neutral Impact 92
Lifecore Biomedical Reports Third Quarter 2026 Financial Results
Lifecore Biomedical announced its third-quarter 2026 financial results, revealing a net loss of $40.1 million, a substantial increase from $10.0 million in the prior year. This was…
Sep 29, 2026 Corporate Catalyst Neutral Impact 75
Wynnefield Capital Discloses About 14.3% Stake In Lifecore Biomedical, Agrees To Vote In Favor Of Its Pending Merger, Per 13D Filing
Wynnefield Capital, a known activist investor, has filed a 13D disclosing a 14.3% ownership stake in Lifecore Biomedical (LFCR) and, crucially, has agreed to vote in favor of the c…
Sep 29, 2026 Corporate Catalyst Bearish Impact 65
Barrington Research Downgrades Lifecore Biomedical to Market Perform
Barrington Research downgraded Lifecore Biomedical (LFCR) from Outperform to Market Perform. This analyst downgrade signals a less optimistic view on the company's prospects, likel…
Sep 28, 2026 Corporate Catalyst Bearish Impact 65
William Blair Downgrades Lifecore Biomedical to Market Perform
William Blair analyst Max Smock downgraded Lifecore Biomedical (LFCR) from Outperform to Market Perform. This matters because analyst ratings can influence investor sentiment and s…
Sep 28, 2026 Corporate Catalyst Neutral Impact 95
Lifecore Biomedical To Be Acquired By Webster Equity Partners In Up To $663.7M Transaction; Stockholders May Receive Up To $9.67 Per Common Equivalent In Combined Cash And CVR At Full Performance Milestone Payments
Lifecore Biomedical (LFCR) is being acquired by Webster Equity Partners in a deal valued at up to $663.7 million. This is a major corporate catalyst for LFCR shareholders, who will…
Aug 5, 2026 Corporate Catalyst Bullish Impact 75
Lifecore Biomedical Q2 EPS $(0.19) Beats $(0.22) Estimate, Sales $34.200M Beat $32.016M Estimate
Lifecore Biomedical (LFCR) announced Q2 earnings that surpassed analyst expectations, with a smaller loss per share and higher sales. This is a positive development for the company…
Aug 5, 2026 Corporate Catalyst Bearish Impact 55
Lifecore Biomedical Affirms FY2026 Sales Guidance of $120.000M-$125.000M vs $122.176M Est
Lifecore Biomedical (LFCR) filed an 8-K to affirm its previously stated sales guidance for fiscal year 2026, keeping the range at $120 million to $125 million. This filing is signi…
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.